These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31891000)

  • 1. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification.
    Coyne DW; Singh HN; Smith WT; Giuseppi AC; Connarn JN; Sherman ML; Dellanna F; Malluche HH; Hruska KA
    Kidney Int Rep; 2019 Nov; 4(11):1585-1597. PubMed ID: 31891000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
    Sherman ML; Borgstein NG; Mook L; Wilson D; Yang Y; Chen N; Kumar R; Kim K; Laadem A
    J Clin Pharmacol; 2013 Nov; 53(11):1121-30. PubMed ID: 23939631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.
    Cappellini MD; Porter J; Origa R; Forni GL; Voskaridou E; Galactéros F; Taher AT; Arlet JB; Ribeil JA; Garbowski M; Graziadei G; Brouzes C; Semeraro M; Laadem A; Miteva D; Zou J; Sung V; Zinger T; Attie KM; Hermine O
    Haematologica; 2019 Mar; 104(3):477-484. PubMed ID: 30337358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
    Raftopoulos H; Laadem A; Hesketh PJ; Goldschmidt J; Gabrail N; Osborne C; Ali M; Sherman ML; Wang D; Glaspy JA; Puccio-Pick M; Zou J; Crawford J
    Support Care Cancer; 2016 Apr; 24(4):1517-25. PubMed ID: 26370220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotatercept in patients with osteolytic lesions of multiple myeloma.
    Abdulkadyrov KM; Salogub GN; Khuazheva NK; Sherman ML; Laadem A; Barger R; Knight R; Srinivasan S; Terpos E
    Br J Haematol; 2014 Jun; 165(6):814-23. PubMed ID: 24650009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant associations between bone mineral density and vascular calcification in patients with different stages of chronic kidney disease.
    Uhlinova J; Kuudeberg A; Metsküla K; Lember M; Rosenberg M
    BMC Nephrol; 2022 Oct; 23(1):327. PubMed ID: 36199013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes.
    Nasrollahizadeh A; Soleimani H; Nasrollahizadeh A; Hashemi SM; Hosseini K
    Clin Cardiol; 2024 Jan; 47(1):e24173. PubMed ID: 37819149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
    Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
    Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
    Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
    Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
    Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
    Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial.
    Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
    Am J Kidney Dis; 2010 Jul; 56(1):57-68. PubMed ID: 20347511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Mineral Density and Aortic Calcification: Evidence for a Bone-vascular Axis After Kidney Transplantation.
    Sotomayor CG; Benjamens S; Gomes-Neto AW; Pol RA; Groothof D; Te Velde-Keyzer CA; Chong G; Glaudemans AWJM; Berger SP; Bakker SJL; Slart RHJA
    Transplantation; 2021 Jan; 105(1):231-239. PubMed ID: 32568501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
    Agapova OA; Fang Y; Sugatani T; Seifert ME; Hruska KA
    Kidney Int; 2016 Jun; 89(6):1231-43. PubMed ID: 27165838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.